Advertisement

Sex-Specific Physiology and Cardiovascular Disease

  • Chrisandra L. Shufelt
  • Christine Pacheco
  • Marysia S. Tweet
  • Virginia M. Miller
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1065)

Abstract

Sex differences in cardiovascular diseases can be classified as those which are specific to one sex and those that differ in incidence, prevalence, etiology, symptomatology, response to treatment, morbidity, and mortality in one sex compared to the other. All sex differences in cardiovascular conditions have their basis in the combined expression of genetic and hormonal differences between women and men. This chapter addresses how understanding basic mechanisms of hormone responses, imaging diagnostics, and integration of genomics and proteomics has advanced diagnosis and improved outcomes for cardiovascular conditions, apart from those related to pregnancy that are more prevalent in women. These conditions include obstructive coronary artery disease, coronary microvascular dysfunction, spontaneous coronary artery dissection, diseases of the cardiac muscle including heart failure and takotsubo cardiomyopathy, and conditions related to neurovascular dysregulation including hot flashes and night sweats associated with menopause and effects of exogenous hormones on vascular function. Improvement in technologies allowing for noninvasive assessment of neuronally mediated vascular reactivity will further improve our understanding of the basic etiology of the neurovascular disorders. Consideration of sex, hormonal status, and pregnancy history in diagnosis and treatment protocols will improve prevention and outcomes of cardiovascular disease in women as they age.

Keywords

Atrial fibrillation Cardiomyopathy Endothelial dysfunction Coronary microvascular dysfunction 17β-Estradiol Heart failure Hot flashes Ischemic nonobstructive coronary artery disease INOCA Menopause Migraine SCAD Spontaneous coronary artery dissection Takotsubo Vasomotor symptoms 

References

  1. 1.
    Bellott DW, Hughes JF, Skaletsky H, Brown LG, Pyntikova T, Cho TJ, Koutseva N, Zaghlul S, Graves T, Rock S, et al. Mammalian Y chromosomes retain widely expressed dosage-sensitive regulators. Nature. 2014;508(7497):494–9.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Arnold AP, Lusis AJ. Understanding the sexome: measuring and reporting sex differences in gene systems. Endocrinology. 2012;153(6):2551–5.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Fu Q. Hemodynamic and electrocardiographic aspects of uncomplicated singleton pregnancy. In: Kerkhof PLM, Miller VM, editors. Sex-specific analysis of cardiovascular function. New York: Springer; 2018. page numbers.Google Scholar
  4. 4.
    Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Pancholy SB, Shantha GP, Patel T, Cheskin LJ. Sex differences in short-term and long-term all-cause mortality among patients with ST-segment elevation myocardial infarction treated by primary percutaneous intervention: a meta-analysis. JAMA Intern Med. 2014;174(11):1822–30.CrossRefPubMedGoogle Scholar
  6. 6.
    Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists’ view. Eur Heart J. 2013;34(10):719–28.CrossRefPubMedGoogle Scholar
  7. 7.
    Roswell RO, Kunkes J, Chen AY, Chiswell K, Iqbal S, Roe MT, Bangalore S. Impact of sex and contact-to-device time on clinical outcomes in acute ST-segment elevation myocardial infarction-findings from the National Cardiovascular Data Registry. J Am Heart Assoc. 2017;6(1).PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Choi K, Shofer FS, Mills AM. Sex differences in STEMI activation for patients presenting to the ED 1939. Am J Emerg Med. 2016;34(10):1939–43.CrossRefPubMedGoogle Scholar
  9. 9.
    Mehta LS, Beckie TM, DeVon HA, Grines CL, Krumholz HM, Johnson MN, Lindley KJ, Vaccarino V, Wang TY, Watson KE, et al. Acute myocardial infarction in women: a scientific statement from the American Heart Association. Circulation. 2016;133(9):916–47.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013;82(1):E1–27.CrossRefPubMedGoogle Scholar
  11. 11.
    Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60(7):645–81.CrossRefPubMedGoogle Scholar
  12. 12.
    Reis SE, Holubkov R, Conrad Smith AJ, Kelsey SF, Sharaf BL, Reichek N, Rogers WJ, Merz CN, Sopko G, Pepine CJ, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J. 2001;141(5):735–41.CrossRefPubMedGoogle Scholar
  13. 13.
    Jespersen L, Hvelplund A, Abildstrom SZ, Pedersen F, Galatius S, Madsen JK, Jorgensen E, Kelbaek H, Prescott E. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. 2012;33(6):734–44.CrossRefPubMedGoogle Scholar
  14. 14.
    von Mering GO, Arant CB, Wessel TR, McGorray SP, Bairey Merz CN, Sharaf BL, Smith KM, Olson MB, Johnson BD, Sopko G, et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation. 2004;109(6):722–5.CrossRefGoogle Scholar
  15. 15.
    Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM, Johnson BD, Sopko G, Bairey Merz CN. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol. 2010;55(25):2825–32.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356(8):830–40.CrossRefPubMedGoogle Scholar
  17. 17.
    Ishimori ML, Martin R, Berman DS, Goykhman P, Shaw LJ, Shufelt C, Slomka PJ, Thomson LE, Schapira J, Yang Y, et al. Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. JACC Cardiovasc Imaging. 2011;4(1):27–33.CrossRefPubMedGoogle Scholar
  18. 18.
    Saiki H, Petersen IA, Scott CG, Bailey KR, Dunlay SM, Finley RR, Ruddy KJ, Yan E, Redfield MM. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation. 2017;135(15):1388–96.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Sandoo A, Kitas GD, Carmichael AR. Breast cancer therapy and cardiovascular risk: focus on trastuzumab. Vasc Health Risk Manag. 2015;11:223–8.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Doyle M, Weinberg N, Pohost GM, Bairey Merz CN, Shaw LJ, Sopko G, Fuisz A, Rogers WJ, Walsh EG, Johnson BD, et al. Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women’s Ischemia Syndrome Evaluation) study. JACC Cardiovasc Imaging. 2010;3(10):1030–6.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Freed BH, Narang A, Bhave NM, Czobor P, Mor-Avi V, Zaran ER, Turner KM, Cavanaugh KP, Chandra S, Tanaka SM, et al. Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013;15:108.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Mehta PK, Bairey Merz CN. Treatment of angina in subjects with evidence of myocardial ischemia and no obstructive coronary artery disease. In: Bonow RO, editor. Braunwald’s heart disease. Philadelphia: Elsevier; 2011.Google Scholar
  23. 23.
    Tweet MS, Hayes SN, Pitta SR, Simari RD, Lerman A, Lennon RJ, Gersh BJ, Khambatta S, Best PJ, Rihal CS, et al. Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation. 2012;126(5):579–88.CrossRefPubMedGoogle Scholar
  24. 24.
    Tweet MS, Hayes SN, Codsi E, Gulati R, Rose CH, Best PJM. Spontaneous coronary artery dissection associated with pregnancy. J Am Coll Cardiol. 2017;70(4):426–35.CrossRefPubMedGoogle Scholar
  25. 25.
    Saw J, Humphries K, Aymong E, Sedlak T, Prakash R, Starovoytov A, Mancini GBJ. Spontaneous coronary artery dissection: clinical outcomes and risk of recurrence. J Am Coll Cardiol. 2017;70(9):1148–58.CrossRefPubMedGoogle Scholar
  26. 26.
    Lettieri C, Zavalloni D, Rossini R, Morici N, Ettori F, Leonzi O, Latib A, Ferlini M, Trabattoni D, Colombo P, et al. Management and long-term prognosis of spontaneous coronary artery dissection. Am J Cardiol. 2015;116(1):66–73.CrossRefPubMedGoogle Scholar
  27. 27.
    Nakashima T, Noguchi T, Haruta S, Yamamoto Y, Oshima S, Nakao K, Taniguchi Y, Yamaguchi J, Tsuchihashi K, Seki A, et al. Prognostic impact of spontaneous coronary artery dissection in young female patients with acute myocardial infarction: a report from the Angina Pectoris-Myocardial Infarction Multicenter Investigators in Japan. Int J Cardiol. 2016;207:341–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Rogowski S, Maeder MT, Weilenmann D, Haager PK, Ammann P, Rohner F, Joerg L, Rickli H. Spontaneous coronary artery dissection: angiographic follow-up and long-term clinical outcome in a predominantly medically treated population. Catheter Cardiovasc Interv. 2017;89(1):59–68.CrossRefPubMedGoogle Scholar
  29. 29.
    Tweet MS, Gulati R, Hayes SN. What clinicians should know about spontaneous coronary artery dissection. Mayo Clin Proc. 2015;90(8):1125–30.CrossRefPubMedGoogle Scholar
  30. 30.
    Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol. 2011;58(7):659–70.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Tweet MS, Eleid MF, Best PJ, Lennon RJ, Lerman A, Rihal CS, Holmes DR Jr, Hayes SN, Gulati R. Spontaneous coronary artery dissection: revascularization versus conservative therapy. Circ Cardiovasc Interv. 2014;7(6):777–86.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    McGrath-Cadell L, McKenzie P, Emmanuel S, Muller DW, Graham RM, Holloway CJ. Outcomes of patients with spontaneous coronary artery dissection. Open Heart. 2016;3(2):e000491.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol. 2016;13(6):321–32.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Camm AJ, Savelieva I. Female gender as a risk factor for stroke associated with atrial fibrillation. Eur Heart J. 2017;38(19):1480–4.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Renoux C, Coulombe J, Suissa S. Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study. Eur Heart J. 2017;38(19):1473–9.PubMedGoogle Scholar
  37. 37.
    Abbott GW. KCNE4 and KCNE5: K(+) channel regulation and cardiac arrhythmogenesis. Gene. 2016;593(2):249–60.PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Sabeh MK, MacRae CA. The genetics of atrial fibrillation. Curr Opin Cardiol. 2010;25(3):186–91.CrossRefPubMedGoogle Scholar
  39. 39.
    Heinrich J. General Accounting Office, GAO-01-286R Drugs Withdrawn From Market. 2001.Google Scholar
  40. 40.
    Liu H, Jin MW, Xiang JZ, Huang Y, Sun HY, Chiu SW, Lau CP, Li GR. Raloxifene inhibits transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes. Eur J Pharmacol. 2007;563(1–3):61–8.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Kocic I, Gruchala M, Petrusewicz J. Selective inhibition of pinacidil effects by estrogen in guinea pig heart. Int J Cardiol. 2006;110(1):22–6.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Ko D, Rahman F, Martins MA, Hylek EM, Ellinor PT, Schnabel RB, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: treatment. Nat Rev Cardiol. 2017;14(2):113–24.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Shah SV, Kruse J, Andrei AC, Li Z, Malaisrie SC, Knight BP, Passman RS, McCarthy PM. Gender differences in outcomes after surgical ablation of atrial fibrillation. J Thorac Cardiovasc Surg. 2016;151(2):391–8. e392CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Zylla MM, Brachmann J, Lewalter T, Hoffmann E, Kuck KH, Andresen D, Willems S, Eckardt L, Tebbenjohanns J, Spitzer SG, et al. Sex-related outcome of atrial fibrillation ablation: Insights from the German Ablation Registry. Heart Rhythm. 2016;13(9):1837–44.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131(6):550–9.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Kerkhof PL, Peace RA, Heyndrickx GR, Handly N. Heart function analysis in cardiac patients with focus on sex-specific aspects. In: Kerkhof PLM, Miller VM, editors. Sex-specific analysis of cardiovascular function. New York: Springer; 2018. page numbers.CrossRefGoogle Scholar
  49. 49.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J Card Fail. 2017;23(8):628–51.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Lam PH, Dooley DJ, Deedwania P, Singh SN, Bhatt DL, Morgan CJ, Butler J, Mohammed SF, Wu WC, Panjrath G, et al. Heart rate and outcomes in hospitalized patients with heart failure with preserved ejection fraction. J Am Coll Cardiol. 2017;70(15):1861–71.CrossRefPubMedGoogle Scholar
  51. 51.
    Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591–602.CrossRefPubMedGoogle Scholar
  52. 52.
    Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins PD, Packer M, Wikstrand J, Coats AJ, et al. Effect of age and sex on efficacy and tolerability of beta blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ. 2016;353:i1855.PubMedCentralCrossRefPubMedGoogle Scholar
  53. 53.
    Keyhan G, Chen SF, Pilote L. Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. Eur J Heart Fail. 2007;9(6–7):594–601.CrossRefPubMedGoogle Scholar
  54. 54.
    Hudson M, Rahme E, Behlouli H, Sheppard R, Pilote L. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure--a population study. Eur J Heart Fail. 2007;9(6–7):602–9.CrossRefPubMedGoogle Scholar
  55. 55.
    Cook JL, Grady KL, Colvin M, Joseph SM, Brisco MA, Walsh MN, gen VADWG. Sex differences in the care of patients with advanced heart failure. Circ Cardiovasc Qual Outcomes. 2015;8(2 Suppl 1):S56–9.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435–43.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Stevenson LW, Miller LW, Desvigne-Nickens P, Ascheim DD, Parides MK, Renlund DG, Oren RM, Krueger SK, Costanzo MR, Wann LS, et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation. 2004;110(8):975–81.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Bogaev RC, Pamboukian SV, Moore SA, Chen L, John R, Boyle AJ, Sundareswaran KS, Farrar DJ, Frazier OH, HeartMate IICI. Comparison of outcomes in women versus men using a continuous-flow left ventricular assist device as a bridge to transplantation. J Heart Lung Transplant. 2011;30(5):515–22.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Blumer V, Mendirichaga R, Hernandez GA, Zablah G, Chaparro SV. Sex-specific outcome disparities in patients receiving continuous-flow left ventricular assist devices: a systematic review and meta-analysis. ASAIO J. 2017. https://doi.org/10.1097/MAT.0000000000000695.
  60. 60.
    Aimo A, Vergaro G, Castiglione V, Barison A, Pasanisi E, Petersen C, Chubuchny V, Giannoni A, Poletti R, Maffei S, et al. Effect of sex on reverse remodeling in chronic systolic heart failure. JACC Heart Fail. 2017;5(10):735–42.CrossRefPubMedGoogle Scholar
  61. 61.
    Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, Sheppard MN, Figtree GA, Parodi G, Akashi YJ, et al. Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016;18(1):8–27.CrossRefGoogle Scholar
  62. 62.
    Abraham J, Mudd JO, Kapur NK, Klein K, Champion HC, Wittstein IS. Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. J Am Coll Cardiol. 2009;53(15):1320–5.CrossRefPubMedGoogle Scholar
  63. 63.
    Becker LC, Pepine CJ, Bonsall R, Cohen JD, Goldberg AD, Coghlan C, Stone PH, Forman S, Knatterud G, Sheps DS, et al. Left ventricular, peripheral vascular, and neurohumoral responses to mental stress in normal middle-aged men and women. Reference Group for the Psychophysiological Investigations of Myocardial Ischemia (PIMI) Study. Circulation. 1996;94(11):2768–77.CrossRefPubMedGoogle Scholar
  64. 64.
    Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G, Wu KC, Rade JJ, Bivalacqua TJ, Champion HC. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005;352(6):539–48.CrossRefPubMedGoogle Scholar
  65. 65.
    Merli E, Sutcliffe S, Gori M, Sutherland GG. Tako-Tsubo cardiomyopathy: new insights into the possible underlying pathophysiology. Eur J Echocardiogr. 2006;7(1):53–61.CrossRefPubMedGoogle Scholar
  66. 66.
    de Gregorio C, Grimaldi P, Lentini C. Left ventricular thrombus formation and cardioembolic complications in patients with Takotsubo-like syndrome: a systematic review. Int J Cardiol. 2008;131(1):18–24.CrossRefPubMedGoogle Scholar
  67. 67.
    Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373(10):929–38.CrossRefGoogle Scholar
  68. 68.
    Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation. 2016;133(14):1397–409.CrossRefPubMedGoogle Scholar
  69. 69.
    Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128(3):589–600.CrossRefPubMedGoogle Scholar
  70. 70.
    Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J, Mahmood F, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485(7398):333–8.PubMedCentralCrossRefPubMedGoogle Scholar
  71. 71.
    Damp J, Givertz MM, Semigran M, Alharethi R, Ewald G, Felker GM, Bozkurt B, Boehmer J, Haythe J, Skopicki H, et al. Relaxin-2 and soluble Flt1 levels in peripartum cardiomyopathy: results of the multicenter IPAC study. JACC Heart Fail. 2016;4(5):380–8.PubMedCentralCrossRefPubMedGoogle Scholar
  72. 72.
    Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, Tsai EJ, Hilfiker-Kleiner D, Kamiya CA, Mazzarotto F, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med. 2016;374(3):233–41.PubMedCentralCrossRefPubMedGoogle Scholar
  73. 73.
    Lange S, Auerbach D, McLoughlin P, Perriard E, Schafer BW, Perriard JC, Ehler E. Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2. J Cell Sci. 2002;115(Pt 24):4925–36.CrossRefPubMedGoogle Scholar
  74. 74.
    Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric. 2007;10(3):197–214.CrossRefPubMedGoogle Scholar
  75. 75.
    Mishra GD, Kuh D. Health symptoms during midlife in relation to menopausal transition: British prospective cohort study. BMJ. 2012;344:e402.PubMedCentralCrossRefPubMedGoogle Scholar
  76. 76.
    Tepper PG, Brooks MM, Randolph JF Jr, Crawford SL, El Khoudary SR, Gold EB, Lasley BL, Jones B, Joffe H, Hess R, et al. Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause. 2016;23(10):1067–74.PubMedCentralCrossRefPubMedGoogle Scholar
  77. 77.
    Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–9.PubMedCentralCrossRefPubMedGoogle Scholar
  78. 78.
    Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause. 2009;16(4):639–43.PubMedCentralCrossRefPubMedGoogle Scholar
  79. 79.
    Jackson EA, El Khoudary SR, Crawford SL, Matthews K, Joffe H, Chae C, Thurston RC. Hot flash frequency and blood pressure: data from the study of women’s health across the nation. J Womens Health (Larchmt). 2016;25(12):1204–9.CrossRefGoogle Scholar
  80. 80.
    Thurston RC, Sutton-Tyrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease. Findings from the study of women’s health across the nation heart study. Circulation. 2008;118:1234–40.PubMedCentralCrossRefPubMedGoogle Scholar
  81. 81.
    Muka T, Oliver-Williams C, Colpani V, Kunutsor S, Chowdhury S, Chowdhury R, Kavousi M, Franco OH. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a systematic review and meta-analysis. PLoS One. 2016;11(6):e0157417.PubMedCentralCrossRefPubMedGoogle Scholar
  82. 82.
    Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011.CrossRefPubMedGoogle Scholar
  83. 83.
    Svartberg J, von Muhlen D, Kritz-Silverstein D, Barrett-Connor E. Vasomotor symptoms and mortality: the Rancho Bernardo Study. Menopause. 2009;16(5):888–91.CrossRefPubMedGoogle Scholar
  84. 84.
    Allison MA, Manson JE, Aragaki A, Langer RD, Rossouw J, Curb D, Martin LW, Phillips L, Stefanick ML, Cochrane BB, et al. Vasomotor symptoms and coronary artery calcium in postmenopausal women. Menopause. 2010;17(6):1136–45.PubMedCentralCrossRefPubMedGoogle Scholar
  85. 85.
    Szmuilowicz ED, Manson JE, Rossouw JE, Howard BV, Margolis KL, Greep NC, Brzyski RG, Stefanick ML, O’Sullivan MJ, Wu C, et al. Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause. 2011;18(6):603–10.PubMedCentralCrossRefPubMedGoogle Scholar
  86. 86.
    Cintron D, Lipford M, Larrea-Mantilla L, Spencer-Bonilla G, Lloyd R, Gionfriddo MR, Gunjal S, Farrell AM, Miller VM, Murad MH. Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis. Endocrine. 2017;55(3):702–11.CrossRefPubMedGoogle Scholar
  87. 87.
    Gao C, Kapoor E, Lipford M, Miller V, Schroeder D, Mara K, Faubion S. Association of vasomotor symptoms and sleep apnea risk in midlife women. Menopause. 2017;25(4). https://doi.org/10.1097/GME.0000000000001020. (in press)
  88. 88.
    Kwon Y, Duprez DA, Jacobs DR, Nagayoshi M, McClelland RL, Shahar E, Budoff M, Redline S, Shea S, Carr JJ, et al. Obstructive sleep apnea and progression of coronary artery calcium: the multi-ethnic study of atherosclerosis study. J Am Heart Assoc. 2014;3(5):e001241.PubMedCentralCrossRefPubMedGoogle Scholar
  89. 89.
    Mercuro G, Podda A, Pitzalis L, Zoncu S, Mascia M, Melis GB, Rosano GM. Evidence of a role of endogenous estrogen in the modulation of autonomic nervous system. Am J Cardiol. 2000;85(6):787–9. A789CrossRefPubMedGoogle Scholar
  90. 90.
    de Zambotti M, Trinder J, Javitz H, Colrain IM, Baker FC. Altered nocturnal blood pressure profiles in women with insomnia disorder in the menopausal transition. Menopause. 2017;24(3):278–87.CrossRefPubMedGoogle Scholar
  91. 91.
    Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013;34(3):211–27.CrossRefPubMedGoogle Scholar
  92. 92.
    Prague JK, Roberts RE, Comninos AN, Clarke S, Jayasena CN, Nash Z, Doyle C, Papadopoulou DA, Bloom SR, Mohideen P, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10081):1809–20.PubMedCentralCrossRefPubMedGoogle Scholar
  93. 93.
    Cintron D, Lahr BD, Bailey KR, Santoro N, Lloyd R, Manson JE, Neal-Perry G, Pal L, Taylor HS, Wharton W, et al. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Menopause. 2017.Google Scholar
  94. 94.
    McCall RB, Clement ME. Role of serotonin1A and serotonin2 receptors in the central regulation of the cardiovascular system. PharmacolRev. 1994;46:231–43.Google Scholar
  95. 95.
    Deecher D, Andree TH, Sloan D, Schechter LE. From menarche to menopause: Exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology. 2008;33:3–17.CrossRefPubMedGoogle Scholar
  96. 96.
    Santoro N. Symptoms of menopause: hot flushes. Clin Obstet Gynecol. 2008;51(3):539–48.CrossRefPubMedGoogle Scholar
  97. 97.
    Tuomikoski P, Ebert P, Groop PH, Haapalahti P, Hautamaki H, Ronnback M, Ylikorkala O, Mikkola TS. Evidence for a role of hot flushes in vascular function in recently postmenopausal women. Obstet Gynecol. 2009;113(4):902–8.CrossRefPubMedGoogle Scholar
  98. 98.
    Tuomikoski P, Ebert P, Groop PH, Haapalahti P, Hautamaki H, Ronnback M, Ylikorkala O, Mikkola TS. Effect of hot flushes on vascular function: a randomized controlled trial. Obstet Gynecol. 2009;114(4):777–85.CrossRefPubMedGoogle Scholar
  99. 99.
    Sassarini J, Fox H, Ferrell W, Sattar N, Lumsden MA. Vascular function and cardiovascular risk factors in women with severe flushing. Clin Endocrinol (Oxf). 2011;74(1):97–103.CrossRefGoogle Scholar
  100. 100.
    Miller VM, Duckles SP. Vascular actions of estrogens: functional implications. PharmacolRev. 2008;60(2):210–41.Google Scholar
  101. 101.
    Martin VT, Pavlovic J, Fanning KM, Buse DC, Reed ML, Lipton RB. Perimenopause and menopause are associated with high frequency headache in women with migraine: results of the American Migraine Prevalence and Prevention Study. Headache. 2016;56(2):292–305.CrossRefPubMedGoogle Scholar
  102. 102.
    Pavlovic JM, Allshouse AA, Santoro NF, Crawford SL, Thurston RC, Neal-Perry GS, Lipton RB, Derby CA. Sex hormones in women with and without migraine: evidence of migraine-specific hormone profiles. Neurology. 2016;87(1):49–56.PubMedCentralCrossRefPubMedGoogle Scholar
  103. 103.
    An X, Fang J, Lin Q, Lu C, Ma Q, Qu H. New evidence for involvement of ESR1 gene in susceptibility to Chinese migraine. J Neurol. 2017;264(1):81–7.CrossRefPubMedGoogle Scholar
  104. 104.
    CoSkun S, Yucel Y, Cim A, Cengiz B, Oztuzcu S, Varol S, Ozdemir HH, Uzar E. Contribution of polymorphisms in ESR1, ESR2, FSHR, CYP19A1, SHBG, and NRIP1 genes to migraine susceptibility in Turkish population. J Genet. 2016;95(1):131–40.CrossRefPubMedGoogle Scholar
  105. 105.
    Sutherland HG, Champion M, Plays A, Stuart S, Haupt LM, Frith A, MacGregor EA, Griffiths LR. Investigation of polymorphisms in genes involved in estrogen metabolism in menstrual migraine. Gene. 2017;607:36–40.CrossRefPubMedGoogle Scholar
  106. 106.
    Hershey A, Horn P, Kabbouche M, O’Brien H, Powers S. Genomic expression patterns in menstrual-related migraine in adolescents. Headache. 2012;52(1):68–79.PubMedCentralCrossRefPubMedGoogle Scholar
  107. 107.
    Loewendorf AI, Matynia A, Saribekyan H, Gross N, Csete M, Harrington M. Roads less traveled: sexual dimorphism and mast cell contributions to migraine pathology. Front Immunol. 2016;7:140.PubMedCentralCrossRefPubMedGoogle Scholar
  108. 108.
    Borkum JM. Migraine triggers and oxidative stress: a narrative review and synthesis. Headache. 2016;56(1):12–35.CrossRefPubMedGoogle Scholar
  109. 109.
    Calhoun AH, Gill N. Presenting a new, non-hormonally mediated cyclic headache in women: end-menstrual migraine. Headache. 2017;57(1):17–20.CrossRefPubMedGoogle Scholar
  110. 110.
    Finsterer J, Zarrouk-Mahjoub S. Mitochondrial vasculopathy. World J Cardiol. 2016;8(5):333–9.PubMedCentralCrossRefPubMedGoogle Scholar
  111. 111.
    Bousser MG, Welch KMA. Relation between migraine and stroke. Lancet Neurol. 2005;4:533–42.CrossRefPubMedGoogle Scholar
  112. 112.
    Bushnell CD, Hurn P, Colton C, Miller VM, del Zoppo G, Elkind MSV, Stern BJ, Herrington D, Ford-Lynch G, Gorelick P, et al. Advancing the study of stroke in women. Summary and recommendations for future research from an NINDS-sponsored multidisciplinary working group. Stroke. 2006. (in press). https://doi.org/10.1161/01.STR.0000236053.37695.15.
  113. 113.
    Androulakis XM, Kodumuri N, Giamberardino LD, Rosamond WD, Gottesman RF, Yim E, Sen S. Ischemic stroke subtypes and migraine with visual aura in the ARIC study. Neurology. 2016;87(24):2527–32.PubMedCentralCrossRefPubMedGoogle Scholar
  114. 114.
    Moyer AM, de Andrade M, Weinshilboum RM, Miller VM. Influence of SULT1A1 genetic variation on age at menopause, estrogen levels, and response to hormone therapy in recently postmenopausal white women. Menopause. 2016;23(8):863–9.PubMedCentralCrossRefPubMedGoogle Scholar
  115. 115.
    Sudhir K, Chou TM, Chatterjee K, Smith EP, Williams TC, Kane JP, Malloy MJ, Korach KS, Rubanyi GM. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation. 1997;96:3774–7.CrossRefPubMedGoogle Scholar
  116. 116.
    Gialeraki A, Valsami S, Pittaras T, Panayiotakopoulos G, Politou M. Oral contraceptives and HRT risk of thrombosis. Clin Appl Thromb Hemost. 2016. https://doi.org/10.1177/1076029616683802.
  117. 117.
    Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol. 2009;53(3):221–31.PubMedCentralCrossRefPubMedGoogle Scholar
  118. 118.
    Samson ME, Adams SA, Merchant AT, Maxwell WD, Zhang J, Bennett CL, Hebert JR. Cardiovascular disease incidence among females in South Carolina by type of oral contraceptives, 2000–2013: a retrospective cohort study. Arch Gynecol Obstet. 2016;294(5):991–7.PubMedCentralCrossRefPubMedGoogle Scholar
  119. 119.
    Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016;94(4):328–39.CrossRefPubMedGoogle Scholar
  120. 120.
    Dokras A. Noncontraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome-risks versus benefits. Fertil Steril. 2016;106(7):1572–9.CrossRefPubMedGoogle Scholar
  121. 121.
    Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int. 2008;14(3):111–6.PubMedCentralCrossRefPubMedGoogle Scholar
  122. 122.
    Rocca WA, Gazzuola-Rocca L, Smith CY, Grossardt BR, Faubion SS, Shuster LT, Kirkland JL, Stewart EA, Miller VM. Accelerated accumulation of multimorbidity after bilateral oophorectomy: a population-based cohort study. Mayo Clin Proc. 2016;91(11):1577–89.PubMedCentralCrossRefPubMedGoogle Scholar
  123. 123.
    Rocca WA, Gazzuola Rocca L, Smith CY, Grossardt BR, Faubion SS, Shuster LT, Kirkland JL, Stewart EA, Miller VM. Bilateral oophorectomy and accelerated aging: cause or effect? J Gerontol A Biol Sci Med Sci. 2017;72(9):1213–7.CrossRefPubMedPubMedCentralGoogle Scholar
  124. 124.
    Rivera CM, Grossardt BR, Rhodes DJ, Brown RD, Roger VL, Melton LJ, Rocca WA. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009;16(1):15–23.PubMedCentralCrossRefPubMedGoogle Scholar
  125. 125.
    Daan NM, Muka T, Koster MP, Roeters van Lennep JE, Lambalk CB, Laven JS, Fauser CG, Meun C, de Rijke YB, Boersma E, et al. Cardiovascular risk in women with premature ovarian insufficiency compared to premenopausal women at middle age. J Clin Endocrinol Metab. 2016;101(9):3306–15.CrossRefPubMedGoogle Scholar
  126. 126.
    Roeters van Lennep JE, Heida KY, Bots ML, Hoek A. collaborators of the Dutch Multidisciplinary Guideline Development Group on Cardiovascular Risk Management after Reproductive D: Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(2):178–86.CrossRefPubMedGoogle Scholar
  127. 127.
    Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016;106(7):1588–99.PubMedCentralCrossRefPubMedGoogle Scholar
  128. 128.
    Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD Jr. Premature menopause or early menopause and risk of ischemic stroke. Menopause. 2012;19(3):272–7.PubMedCentralCrossRefPubMedGoogle Scholar
  129. 129.
    Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community. Am J Epidemiol. 1988;128:606–14.CrossRefPubMedGoogle Scholar
  130. 130.
    Falkeborn M, Persson I, Adami HO, Bergstrom R, Eaker E, Lithell H, Mohsen R, Naessen T. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol. 1992;99(10):821–8.CrossRefPubMedGoogle Scholar
  131. 131.
    Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol. 1988;159(2):312–7.CrossRefPubMedGoogle Scholar
  132. 132.
    Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol. 1987;70(3 Pt 1):289–93.PubMedGoogle Scholar
  133. 133.
    Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313(17):1044–9.CrossRefPubMedGoogle Scholar
  134. 134.
    Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol. 1991;164:489–94.CrossRefPubMedGoogle Scholar
  135. 135.
    Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1102–9.CrossRefPubMedGoogle Scholar
  136. 136.
    Hodis H, Mack W, Lobo R, Shoupe D, Sevanian A, Mahrer P, Selzer R, Liu C, Liu C, Azen S. Estrogen in the prevention of atherosclerosis. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135(11):939–53.CrossRefPubMedGoogle Scholar
  137. 137.
    Miller VM, Harman SM. An update on hormone therapy in postmenopausal women: mini-review for the basic scientist. AmJPhysiol (Heart CircPhysiol 42). 2017;313(5):H1013–21.CrossRefGoogle Scholar
  138. 138.
    Anderson G, Cummings S, Freedman LS, Furberg C, Henderson M, Johnson SR, Kuller L, Manson J, Oberman A, Prentice RL, et al. Design of the women’s health initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61–109.CrossRefGoogle Scholar
  139. 139.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.CrossRefPubMedGoogle Scholar
  140. 140.
    Langer RD, Simon JA, Pines A, Lobo RA, Hodis HN, Pickar JH, Archer DF, Sarrel PM, Utian WH. Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. Menopause. 2017;24(10):1101–12.CrossRefPubMedPubMedCentralGoogle Scholar
  141. 141.
    Langer RD. The evidence base for HRT: what can we believe? Climacteric. 2017;20(2):91–6.CrossRefPubMedPubMedCentralGoogle Scholar
  142. 142.
    Clarkson TB, Melendez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause. 2013;20(3):342–53.CrossRefPubMedGoogle Scholar
  143. 143.
    Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med. 2006;166:357–65.CrossRefPubMedGoogle Scholar
  144. 144.
    Manson J, Allison M, Rossouw JE, Carr J, Langer R, Hsia J, Kuller L, Cochrane B, Hunt J, Ludlam S, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591–602.PubMedCentralCrossRefPubMedGoogle Scholar
  145. 145.
    Rossouw J, Prentice R, Manson J, Wu L, Barad D, Barnabei V, Ko M, LaCroix A, Margolis K, Stefanick M. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465.CrossRefPubMedGoogle Scholar
  146. 146.
    Schierbeck L, Rejnmark L, Tofteng C, Stilgren L, Eiken P, Mosekilde L, Kober L, Jensen J. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ. 2012;345:e6409.PubMedCentralCrossRefPubMedGoogle Scholar
  147. 147.
    Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y, Feng M, Dustin L, Kono N, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–31.PubMedCentralCrossRefPubMedGoogle Scholar
  148. 148.
    Faigle JW, Schenkel L. Pharmacokinetics of estrogens and progestogens, vol. 1. London: Chuyrchill Livingston; 1998.Google Scholar
  149. 149.
    Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428–32.CrossRefPubMedGoogle Scholar
  150. 150.
    Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–5.CrossRefPubMedGoogle Scholar
  151. 151.
    Straczek C, Oger E, de Jonage-Canonico BY, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, Levesque H, Trillot N, Barrellier M-T, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration. Circulation. 2005;112:3495–500.CrossRefPubMedGoogle Scholar
  152. 152.
    de Andrade M, Armasu SM, McCauley BM, Petterson TM, Heit JA. Identification of genetic interaction with risk factors using a time-to-event model. Int J Environ Res Public Health. 2017;14(10). https://doi.org/10.3390/ijerph14101228.
  153. 153.
    Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric. 2005;8:3–12.CrossRefPubMedPubMedCentralGoogle Scholar
  154. 154.
    Miller VM, Black DM, Brinton EA, Budoff MJ, Cedars MI, Hodis HN, Lobo RA, Manson JE, Merriam GR, Naftolin F, et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res. 2009;2(3):228–39.PubMedCentralCrossRefPubMedGoogle Scholar
  155. 155.
    Bray PF, Larson JC, Lacroix AZ, Manson J, Limacher MC, Rossouw JE, Lasser NL, Lawson WE, Stefanick ML, Langer RD, et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol. 2008;101(11):1599–605.PubMedCentralCrossRefPubMedGoogle Scholar
  156. 156.
    Wild RA, Wu C, Curb JD, Martin LW, Phillips L, Stefanick M, Trevisan M, Manson JE. Coronary heart disease events in the Women’s Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women’s Health Initiative randomized clinical trials. Menopause. 2013;20:254–60.PubMedCentralPubMedGoogle Scholar
  157. 157.
    Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JEM, Merriam GR, Miller VM, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249–60.CrossRefPubMedPubMedCentralGoogle Scholar
  158. 158.
    Santoro N, Allshouse A, Neal-Perry G, Pal L, Lobo RA, Naftolin F, Black DM, Brinton EA, Budoff MJ, Cedars MI, et al. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. Menopause. 2017;24(3):238–46.PubMedCentralCrossRefPubMedGoogle Scholar
  159. 159.
    Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, Brinton EA, Cedars MI, Lobo RA, Merriam GR, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-Cognitive and Affective Study. PLoS medicine. 2015;12(6):e1001833.PubMedCentralCrossRefPubMedGoogle Scholar
  160. 160.
    Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Du W, Hodis HN, et al. Effects of oral vs transdermal estrogen therapy on sexual function in early postmenopause: ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Intern Med. 2017;177(10):1471–9.CrossRefPubMedGoogle Scholar
  161. 161.
    Miller VM, Petterson TM, Jeavons EN, Lnu AS, Rider DN, Heit JA, Cunningham JM, Huggins GS, Hodis HN, Budoff MJ, et al. Genetic polymorphisms associated carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study. Physiol Genomics. 2013;45(2):79–88.CrossRefPubMedGoogle Scholar
  162. 162.
    Miller VM, Jenkins GD, Biernacka JM, Heit JA, Huggins GS, Hodis HN, Budoff MJ, Lobo RA, Taylor HS, Manson JE, et al. Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. Physiol Genomics. 2016;48(1):33–41.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Chrisandra L. Shufelt
    • 1
  • Christine Pacheco
    • 1
  • Marysia S. Tweet
    • 2
  • Virginia M. Miller
    • 3
  1. 1.Barbra Streisand Women’s Heart CenterCedars-Sinai Medical Center, Smidt Heart InsitituteLos AngelesUSA
  2. 2.Department of Cardiovascular MedicineCollege of Medicine, Mayo ClinicRochesterUSA
  3. 3.Surgery and PhysiologyWomen’s Health Research Center, College of Medicine, Mayo ClinicRochesterUSA

Personalised recommendations